BioGaia AB Interim Management Statement - January – September 2021
Third quarter 2021 · Net sales amounted to SEK 173.8 million (132.0), an increase of 32% (excluding foreign exchange effects, 35%) · Net sales in the Paediatrics segment reached SEK 130.8 million (101.9), an increase of 28%. · Net sales in the Adult Health segment amounted to SEK 42.1 million (29.3), an increase of 43%. · Operating expenses amounted to SEK 60.7 million (62.5), a decrease of 3%. · Operating profit increased by 148% to SEK 67.2 million (27.0), which corresponds to an operating margin of 39% (20%) · Profit after tax amounted to SEK 52.8 million (20.5), an